From the Journals

Serotonin syndrome risk with triptans and antidepressants ‘very low’

 

Key clinical point: The risk of serotonin syndrome in patients who are coprescribed triptans and an SSRI or SNRI antidepressant is extremely low.

Major finding: The incidence of serotonin syndrome in patients coprescribed triptans and antidepressants was 0.6 cases per 10,000 person-years of exposure.

Data source: Analysis of electronic health record data of 47,968 patients prescribed triptans.

Disclosures: The study was supported by the Harvard Catalyst and the Harvard Clinical and Translational Science Center. No conflicts of interest were declared.

Source: Orlova Y et al. JAMA Neurol. 2018 Feb 26. doi: 10.1001/jamaneurol.2017.5144.


 

FROM JAMA NEUROLOGY

The risk of serotonin syndrome developing in individuals who are taking both triptans for migraine and either an SSRI or serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant is very low, according to analysis of electronic health record data of 47,968 patients prescribed triptans.

The study of 14 years’ worth of data, published online Feb. 26 in JAMA Neurology, identified only two confirmed cases of serotonin syndrome, representing an incidence rate of 0.6 cases per 10,000 person-years of exposure, and five probable cases.

“Our results do not show major changes in prescribing patterns as a result of the FDA advisory [warning in 2006]. Taken as a whole, our data suggest that the FDA advisory should be reconsidered,” wrote Yulia Orlova, MD, PhD, of the University of Florida, Gainesville, and her coauthors. Dr. Orlova was with the Graham Headache Center at Brigham and Women’s Hospital in Boston at the time she conducted the research.

Overall, the investigators found 19,017 patients who were prescribed both triptans and an SSRI or SNRI. Of these, 229 (1.2%) were diagnosed with extrapyramidal syndrome at some point. Serotonin syndrome was suspected in 17 patients, while other diagnoses included restless legs syndrome, periodic limb movement disorder of sleep, and akathisia.

Four cases met both the Sternbach and Hunter diagnostic criteria for serotonin syndrome, but in only two of these cases had triptans been used at around the time that the serotonin syndrome symptoms developed. However, the authors did note that, in both these cases, some symptoms developed before the patients ingested the triptans.

Even if serotonin syndrome was in fact the cause of symptoms in all the patients with suspected diagnoses, and who had documented coprescription of triptans and antidepressants, this still represented an incidence of 2.3 cases per 10,000 person-years.

“Our results provide additional reasons to be skeptical that triptans increase the risk of serotonin syndrome beyond the risk already associated with SSRIs and SNRIs alone,” Dr. Orlova and her colleagues wrote.

The investigators also pointed out that the biological plausibility of triptans as a cause of serotonin syndrome was questionable.

“Evidence suggests that serotonin syndrome is mediated by serotonin 2A receptors, with possible involvement of serotonin-1A receptors,” they wrote. “Triptans, however, are serotonin agonists with high affinity at serotonin-1B and -1D receptors and only low affinity for serotonin-1A receptors.”

They noted that many of the patients with suspected serotonin syndrome were taking a large number of other medications that could also have contributed to the symptoms.

“Acute dystonic reactions, akathisia, or drug-induced tremors are not rare in patients who are receiving treatment for migraine that includes phenothiazines or neuroleptic drugs for migraine-associated nausea or pain.”

However, they did qualify their findings by noting that the quality of medical documentation was “highly variable,” and they often had to make the diagnosis based on poor descriptions of symptoms or physical examination findings.

“Overall, our results are reassuring and suggest that patients with coexisting affective disorders and migraine need not forgo management of one condition to treat the other.”

The study was supported by the Harvard Catalyst and the Harvard Clinical and Translational Science Center. No conflicts of interest were declared.

SOURCE: Orlova Y et al. JAMA Neurol. 2018 Feb 26. doi: 10.1001/jamaneurol.2017.5144.

Next Article:

   Comments ()

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge